Lenacapavir: Playing the Long Game in the New Era of Antiretrovirals
Clinical Pharmacology & Therapeutics · 2025-02 · 117 (2) · 353-367
DOI: 10.1002/cpt.3447 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 25.09.2024. Verfasst von Noah C Neverette und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Pharmaceutical Sciences, Department of Pharmacy & Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsyl…. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections, HIV-1, Acetamides. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
The mainstay of antiretroviral therapy (ART) has been combination oral therapy. While oral ART is highly effective, nonadherence remains a chief concern. Addressing this concern in recent years is the emergence of long‐acting antiretrovirals for the treatment and prevention of HIV‐1 infection. The most recently approved long‐acting antiretroviral is the first‐in‐class capsid inhibitor lenacapavir (LEN) for heavily treatment‐experienced adults with multidrug‐resistant HIV‐1 infection. Due to its biannual subcutaneous dosing scheme to inhibit the HIV‐1 capsid, LEN exhibits unique pharmacokinetics and reinforces an evolving era of ART. In this review, we evaluate published and accepted research articles, conference proceedings, and clinical trial records to provide a comprehensive overview of LEN for treatment and preliminary data for the prevention of HIV‐1 infection. These data include clinical trials outcomes, in vitro and in vivo resistance profiles, and preclinical data supporting downstream indications. We also discuss the unique clinical pharmacology of LEN with the goal of serving as a resource toward subsequent physiologically based, population‐based, and other miscellaneous pharmacometric‐focused analyses. Given the dynamic nature of the HIV treatment and prevention research fields, we also discuss ongoing studies related to LEN for treatment‐naïve adults and for prevention. Lastly, we discuss important pharmacologic gaps in special populations, drug–drug interactions, and at the sites of action germane to HIV treatment and prevention. The information discussed in this review will provide knowledge and understanding of the unique pharmacologic properties of LEN to assist clinicians and researchers as they navigate the dynamic HIV research landscape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Clinical Pharmaceutical Sciences, Department of Pharmacy & Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
- Division of Infectious Diseases, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Noah C Neverette, Julie B Dumond, Deborah K McMahon, Aaron S Devanathan
Förderung
- NHLBI NIH HHS
- NIAID NIH HHS
Zitieren
APA
Neverette, N. C., Dumond, J. B., McMahon, D. K., & Devanathan, A. S. (2025). Lenacapavir: Playing the Long Game in the New Era of Antiretrovirals. Clinical Pharmacology & Therapeutics, 117(2), 353-367. https://doi.org/10.1002/cpt.3447
Vancouver
Neverette NC, Dumond JB, McMahon DK, Devanathan AS. Lenacapavir: Playing the Long Game in the New Era of Antiretrovirals. Clinical Pharmacology & Therapeutics. 2025;117(2):353-367. doi:10.1002/cpt.3447
BibTeX
@article{Neverette2025,
author = {Neverette, Noah C and Dumond, Julie B and McMahon, Deborah K and Devanathan, Aaron S},
title = {Lenacapavir: Playing the Long Game in the New Era of Antiretrovirals},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
volume = {117},
number = {2},
pages = {353--367},
doi = {10.1002/cpt.3447}
}
EUVIMED